CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 218 enrolled
Drug / intervention
ReSTORdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00719732
NCT00719732Phase 4Completed
CompareCT.gov

Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3

Alcon Research·interventional·Posted Jul 22, 2008·Updated Mar 16, 2010

In Brief

A Phase 4 clinical trial evaluating ReSTOR for Cataract. Completed, enrolled 218 participants across 1 site.

Detailed Summary

A prospective evaluation of the visual parameters in a series of patients bilaterally implanted with AcrySof ReSTOR +3 Intraocular Lens (IOL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2008
Enrollment StartSep 1, 2007
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.9 years ago

Interventions

ReSTORdevice

Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).